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Diversity oriented synthesis of fused pyrimidines leads to scaffolds with many biological 
activities. In the case of the preparation of pyrido[2,3-d]pyrimidines from 2-
alkylthiopyrimidines, the formation of a new carbon-carbon bond at C5 is required, a reaction 
that is very limited in scope.  However Claisen type rearrangement of simple 4-allylic ethers 
affords C5 substituted pyrimidines readily; in cases with an ester substituent, rearrangement 
occurs at room temperature.  Subsequent cyclisation to afford 6-methylpyrido[2,3-
d]pyrimidin-7(8H)-ones was achieved in high yield. Using allylic ethers derived from 3-
chloromethyl-4-arylbut-3-en-2-ones as substrates, a new titanium[IV]chloride catalysed 
reaction affording 6-arylmethyl-7-methylpyrido[2,3-d]pyrimidines was discovered. In 
contrast, 2-alkylthiopteridines are readily available. In both cases, substitution at C2 and C4 
to generate diversity has been carried out and the reactivity compared; yields of substitution 
products were generally higher with pteridine substrates. In biological assays unexpected hits 
were found for activity against the Gram positive bacterium, Nocardia farcinia, and against 
the parasite Trypanosoma brucei brucei, illustrating the value of diversity oriented synthesis 
in the discovery of biologically active compounds. 
 
 
 
Keywords: pyrimidines, Claisen allyl rearrangement, pyridopyrimidines, pteridines, diversity 
oriented synthesis, antiparasitic activity. 
 
 
 
 
 
 
 
 
 3
1. Introduction 
Whilst the synthesis of pteridines and related bicyclic nitrogen heterocycles is 
established,1 the synthesis of their deaza analogues requires further development because 
most methods for the synthesis of such compounds have not been designed with the 
intention of creating highly diverse libraries of compounds as is required for modern 
medicinal chemistry in which multiple biological targets may be relevant.  With emphasis 
on diversity oriented synthesis in our own studies, we have identified active compounds 
with respect to GTP cyclohydrolase 1,2 dihydropterin diphosphokinase,3 dihydrofolate 
reductase,4 pteridine reductase 15 and nitric oxide synthase.6  Several of these targets are 
significant clinically and the optimisation of activity requires the availability of more 
diverse libraries within the same basic structural skeleton.  Our recent work, therefore, 
has emphasised maximising the number of easily variable sites, so that at least three 
variations are readily available from one synthetic stream.  At the centre of these 
developments has been the alkylthio substituent, either at C2 or C4 of a pyrimidine and 
we have established a prototype solid phase synthesis of pteridines using this linker 
which proceeds through C5 nitrosation of the alkylthiopyrimidine.7 Extension of this 
chemistry to pyrido[2,3-d]pyrimidines and pyrrolo[2,3-d]pyrimidines requires carbon 
substitution to take place at C5 of the pyrimidine.  Although a 2- or 4-alkylthio 
substituent gives access to diversity, via oxidation and nucleophilic displacement, the 
presence of the alkylthio substituent significantly reduces the reactivity of C5 to 
electrophiles compared with the more common 2-amino substituent such that carbon 
electrophiles, do not react.  A significant exception is that when certain Michael acceptors 
are used, C5 substitution occurs in reduced yield8 and this chemistry has been developed 
to provide compounds with significant activity against Trypanosoma brucei.5  A further 
example of a successful C5 substitution of a 2-alkylthiopyrimidine is found in nucleoside 
analogue synthesis and involves Vilsmeier formylation.9  In contrast, halogen 
electrophiles substitute 2-alkylthiopyrimidines in high yield and provide suitable 
precursors for C5 carbon substitution.10  In view of the low reactivity of these 
intermolecular substitution reactions, we hypothesised that intramolecular C5 substitution 
might be successful and that suitable precursours for the Claisen allyl rearrangement 
would be available from O4 allyl ethers.  Allyl rearrangements have been used in the 
synthesis of many natural products.11 The Claisen rearrangement was first described in the 
pyrimidine series in 1961 but the reactions lacked functional groups for further 
transformations leading to fused pyrimidines. 12 
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2. Results and discussion 
2.1 Claisen rearrangement 
 
To investigate further the Claisen rearrangement approach,12 pyrimidine 1 was treated 
with allyl bromide in DMF in the presence of solid potassium carbonate to afford a 
mixture of the O4 and N3 allyl pyrimidines 2 (62%) and 3 (9%), which were separable by 
column chromatography.  The O4 allylated pyrimidine 2 underwent quantitative Claisen 
rearrangement to afford 4 at 200 oC in the melt (Scheme 1); in previous work, reactions 
took place in high boiling solvents and gave only 20% yield.   
 
Scheme 1. Substitution by Claisen rearrangement. Reagents and conditions:  i.  DMF, K2CO3, 
100 °C, 20 h;  ii.  200 °C, 24 h 
Cyclisation of 4 to either a pyrido[2,3-d]- or a pyrrolo[2,3-d]-pyrimidine proved 
unsuccessful using palladium catalysis.10  However, this cyclisation reaction was not a 
priority because the products of cyclisation of 4 would lack substituents in the newly 
formed ring, an outcome inappropriate for a diversity oriented synthesis;  substituted 
allylic groups are necessary for library synthesis.  In electrocyclic reactions, it is often 
found that the introduction of an electron withdrawing group to an alkene greatly 
increases the reaction rate.11  By using ethyl bromomethylacrylate as the alkylating agent 
and pyrimidine 1, two surprising results were obtained.  Firstly, alkylation of the anion of 
1 with ethyl bromomethylacrylate led directly to the disubstituted pyrimidine, 5 (Scheme 
2); such a product could arise if rearrangement was exceptionally rapid and was followed 
by a subsequent O-alkylation.  The structure of 5 was confirmed by X-ray 
crystallography.13  
 5
 
Scheme 2. Preparation of dialkylated pyrimidine 5 Reagents and conditions:  i.  DMF, 
K2CO3, 55 °C, 24h 
 
This reaction suggested that both allyl ether formation and rearrangement surprisingly 
had taken place at room temperature.  Pyrimidine 1 was therefore treated slowly over 
a period of days with ethyl bromomethylacrylate at room temperature in the absence 
of added base to afford the rearranged C5 alkylated product 6a  (46%).  Similar 
reactions occurred between 1 and bromomethylacrylic acid to give 6b (30%), as well 
as on the 2-aminopyrimidine 7a to give 6c and 6d in 83 and 53% yield respectively 
(Scheme 3).  A set of 6-N-alkylpyrimidines (7b, 7c, 7d) was also prepared in a 
similar manner.  As planned, the C5 alkylated products were cyclised with non-
nucleophilic base to afford a set of pyrido[2,3-d]pyrimidine-7(8H)-ones (6f – 6g).   
Optimisation of the cyclisation conditions of the C5 alkylated Claisen rearrangement 
products 6 showed that triazabicyclodecane (TBD) was more effective than 
diazabicycloundecane (DBU) and yields of  >80% were reproducibly obtained 
leading to a series of 2-alkylthiopyrido[2,3-d]-3(4H),7(8H)-diones (Scheme 3) from 
which a library of compounds through C2 substitution was generated (8a – 8e).  
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1 R1 = SBn, R2 = H
7a R1 = NH2, R2 = H
7b R1 = SBn, R2 = Me
7c R1 = SBn, R2 = CH2Ph
7d R1 = SBn, R2 = CH2CHCH2
6a R1 = SBn, R2 = H, R3 = Et, 46%
6b R1 = SBn, R2 = H, R3 = H, 30%
6c R1 = NH2, R2 = H, R3 = Et, 83%
6d R1 = NH2, R2 = H, R3 = H 53%
6e R1 = SBn, R2 = Me, R3 = Et, 33%
6f R1 = SBn, R2 = CH2Ph, R3 = Et, 33%
6g R1 = SBn, R2 = CH2CHCH2, R3 = Et, 33%
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N N O
R2
O
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8a R1 = SBn, R2 = H, 98%
8b R1 = NH2, R2 = H, 81%
8c R1 = SBn, R2 = Me, 96%
8d R1 = SBn, R2 = CH2Ph, 96%
8e R1 = SBn, R2 = CH2CHCH2, 96%
ii
 
Scheme  3. Reagents and conditions:  i. DMF, r.t, 7 d; ii.  TBD or DBU, MW, 100 °C, 30 
min 
2.2 Lewis acid catalysed rearrangement and cyclisation 
In principle, the bromomethylacrylate substitution and Claisen rearrangement leads to 
pyrido[2,3-d]pyrimidindiones with diversity at two positions and efforts were made to 
extend the reaction using more highly substituted acrylates without success.  However the 
Claisen rearrangement route has further potential for the synthesis of diverse pyrido[2,3-
d]pyrimidines if ketones are used in place of esters.  β-Halomethyl arylidene ketones are 
readily available through the Baylis-Hillman reaction using methyl vinyl ketone and the 
appropriately substituted aldehyde.14  Such compounds 9a, 9b were found to react readily 
with the benzylthiopyrimidinone 1 in the presence of cesium carbonate to afford the O-
alkyl products 10a, 10b  in 60 – 70% yield.  Unlike the previous examples, these 
compounds are stable at room temperature and do not rearrange cleanly on thermolysis.  
Base catalysis via an N6 anion formed using sodium hydride or DBU did not promote any 
reaction. Many metal complexes have been used to accelerate electrocyclic reactions 
including the Claisen rearrangement. 11,15 Several Lewis acids were tested for their ability 
to promote rearrangement of the arylallyl ethers, 10; boron trifluoride, magnesium 
dibromide, stannic chloride, and zinc chloride failed but titanium tetrachloride (10 
mol)16,17 induced both a rearrangement and concomitant cyclisation to afford the 6-
 7
arylmethylpyrido[2,3-d]pyrimidines 11a, 11b in modest yield (Scheme 4). It is notable 
that these are not the expected products of Claisen rearrangement and subsequent 
cyclisation, which would be 5-aryl-6,7-dimethylpyrido[2,3-d]pyrimidines.  Titanium 
tetrachloride catalysis has therefore caused the reaction to follow another course; the 
proposed mechanism for the reaction is shown in Scheme 5. 
 
 
Scheme 4. Reagents and conditions:  i.  Cs2CO3, KI, r.t., 24 h;  ii.  TiCl4.2THF, THF, 
reflux, 3 d 
 8
 
Scheme 5. Proposed mechanism for the synthesis of derivatives 11. Ti was introduced as 
TiCl4.2THF in THF solution. 
 
Increasing the molar proportion of titanium tetrachloride up to 50 mol.% also failed to 
improve yields.  Indeed the major product under conditions of higher concentration of 
titanium tetrachloride was the precursor Baylis-Hillman chloroketone, 9.  The occurrence 
of these competing reactions can be rationalised by a mechanism in which titanium 
tetrachloride generates an electrophile from the allyl ether, possibly with coordination 
also of the ketone carbonyl group to maintain an essentially intramolecular reaction.  The 
initial coordination of titanium tetrachloride to the pyrimidyl ether would liberate 
chloride which, at the higher concentrations, traps the intermediate delocalised allylic 
cation 12 reverting to the starting material 9.  Nevertheless, two new pyrido[2,3-
d]pyrimidines 11  were obtained for investigation of the introduction of diversity by 
modifications at C2 and C4. 
2.3 Diversification 
Having established ring syntheses of pyrido[2,3-d]pyrimidines 11 from allyl ethers it was 
necessary to demonstrate diversification of these compounds at the 2-position.  Two 
reactions were investigated, firstly oxidation of benzylthio substituents followed by 
nucleophilic substitution and secondly conversion of a 4-oxo substituent into a 4-
aminoalkyl substitutent using BOP (benzotriazole-1-yl-
 9
oxytris(dimethylamino)phosphonium hexafluorophosphate) and the corresponding 
amine.18  The oxidation/substitution sequence is successful and in high yield (typically 85 
– 95%) with pteridines and other compounds with electron deficient rings fused to 
pyrimidines.19-21   In many cases with pteridines as substrates, oxidation was not required 
before nucleophilic substitution of the alkylthio group. In this study, the range of 
examples has been extended to 4-aminoalkyl pteridines as substrates, the latter being 
available through BOP chemistry as noted above.18 
 
At the other extreme of reactivity, pyrrolo[2,3-d]pyrimidines underwent substitution only 
after oxidation, under vigorous conditions and in much lower yields.5  It would be 
reasonable to expect that the reactivity of pyrido[2,3-d]pyrimidines to nucleophilic 
substitution after oxidation would lie between these two extremes and this indeed proved 
to be the case.  The 7-oxopyrido[2,3-d]pyrimidines 8d and 8e gave 13a – 13d in yields 
typically of 50 – 60%, somewhat greater than those for the pyrido[2,3-d]pyrimidines 11b 
lacking the 7-oxo group, which afforded typically 35 – 55% yields of 14a – 14d under the 
same conditions.   
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R
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N N
O
R1 O
R2
8d R = CH2Ph
8e R = CH2CH=CH2
13a R1 = NHCH2Ph, R2 = CH2Ph, 68%
13b R1 = pyrrolidin-1-yl, R2 = CH2Ph, 59%
13c R1 = NHCH2Ph, R2 = CH2CH=CH2, 62%
13d R1 = pyrrolidin-1-yl, R2 = CH2CH=CH2, 68%
i, ii
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N N
O
PhCH2S CF3
i, ii
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N N
O
R CF3
11b 14a R = NHCH2Ph, 44%
14b R = pyrrolidin-1-yl, 51%
14c R = NHPh, 37%
14d R = OH, 44%
HN
N N
O
PhCH2HN O
CH2Ph
13a
N
N N
R
PhCH2HN O
CH2Ph
15a R = NHCH2Ph, 65%
15b R = pyrrolidin-1-yl, 58%  
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Scheme 6. Diversification reactions for pyridopyrimdines. Reagents and conditions:  i. 
DMF, m-CPBA, r.t., 3 h;  ii, appropriate amine, MW, 110 °C, 1 h;  iii, BOP, CHCN, r.t., 
10 min;  iv,  DBU, appropriate amine, r.t., 48 h. 
 
A further reaction of value in the diversification of oxo-heterocycles has been 
demonstrated by scientists from Wyeth who showed that oxo substituents in 4- and 7- 
positions especially could be converted into aminoalkyl substituents by treatment with 
BOP and the required amine.18  This reaction was successful with 13a as a representative 
pyridopyrimidine substrate affording pentasubstituted pyrido[2,3-d]pyrimidines 15a and 
15b in satisfactory yield (55 – 65%, Scheme 6).  
 
In the pteridine series, both oxidative substitution and BOP-activated substitution were 
successful; the former gave a series of 2-alkylamino-4-oxopteridines (17a – h) in good 
yield and the latter, 4-aminoalkyl pteridines (18a – f) in acceptable to good yields (65 – 
80%) (Scheme 7).  That the order of substitution at C2 and C4 was not critical was shown 
by the successful oxidative substitution of the new 4-alkylaminopteridines by a variety of 
amines to give 19a - e although yields were poorer for the BOP-mediated substitution (~ 
30%).    
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Scheme 7. Diversification reactions for pteridines. Reagents and conditions: i, HNO2; ii, 
Na2S2O4; iii, EtOH, reflux; iv, DMF, m-CPBA, r.t., 3 h;  v, appropriate amine, MW, 110 °C, 1 
h;  vi, BOP, CH3CN, r.t., 10 min;  vii,  DBU, appropriate amine, r.t., 48 h. 
As a third example of a class of compounds for diversification, two pyrimido-oxazines, 
20 and  21 were substituted directly with benzylamine without oxidative alkylation. In 
addition to substitution at C2, in the case of 21, the C6 ester substituent underwent 
condensation affording the 6-benzylcarboxamide, 23 (Scheme 8). Direct substitution of 
methylthio groups in related pterins in moderate yield has been reported previously.21 
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NHN
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O
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N CO2EtHN
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O
PhCH2HN O
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iii
iii
 
Scheme 8. Diversification for pyrimidooxazines. Reagents and conditions: i, HNO2; ii, 
Na2S2O4; iii, aq. EtOH, NaOAc, reflux; i iv PhCH2NH2, MW, 110 oC, 1 h. 
 
2.4 Conclusions and Biological activity 
In summary, we find that of the fused pyrimidines we have examined in this and in 
previous work, alkylthiopteridines undergo nucleophilic substitution most readily.19,22 
Thus in pteridines, substitution after oxidation of the alkylthio group occurred at room 
temperature in 30 – 60% yield with water, azide, primary and secondary amines as 
nucleophiles. Pyrido[2,3-d]pyrimidines, as described above, are somewhat less reactive, 
requiring higher temperature and concentration of nucleophile to obtain a good yield. To 
a small extent, the 7-oxo group, which can assist in the delocalisation of charge in the 
intermediate in nucleophilic substitution, appears to give better yields. Pyrrolo[2,3-
d]pyrimidines were the least reactive substrates requiring the use of neat amine as 
nucleophile and temperatures above 130 oC to effect substitution;5, 23 this behaviour is 
consistent with the more electron rich pyrrole fused to the pyrimidine ring. In the 
pteridine series, substitution at C2 and C4 can be undertaken in either order using 
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oxidation/substitution or BOP activation/substitution chemistry. Taken together, all of 
these methods provide access to a wide range of fused pyrimidines diversely substituted 
at a late stage in the pyrimidine ring.  
 
We have described elsewhere how this approach has led to compounds with significant 
biological activity, especially in antiparasitic applications.5, 23 The biological activity of 
the compounds prepared in this study has been assessed in screens for antibacterial and 
antiparasitic properties. None of the pyrimido-oxazines was found to be active in any 
assay used.  There was no significant antibacterial activity observed against 
Staphylococcus aureus, or Escherichia coli, but two of the 4-oxopteridines, 17g and 17h 
had weak but measurable activity against the Gram positive bacterium, Nocardia farcinia 
(MIC = 50 and 100 µM respectively). On the other hand, several 4-amino substituted 
compounds were hits in a cell based assay against the parasite Trypanosoma brucei 
brucei. In the pteridine series, both 2-alkylamino and 2-thiobenzyl compounds were 
active (18a, MIC = 25 µM; 18c, 12.5; 18d, 25; 18e, 12.5; 18f, 12.5; 19c, 3.1; 19d, 3.1; 
19e, 6.3); the most active compounds were the 2,4-dialkylamino compounds, 19c – e. The 
pyridopyrimidin-2,4-dione 14d was a also modest hit with a MIC of 25 µM. All of these 
compounds are, however, inferior as antiparasitic compounds to the pyrrolopyrimidines 
we have already described 23 because they have unacceptably high values of clogP (6 – 
7).  Nevertheless, the results reported here serve to illustrate the value of diversity 
oriented synthesis on heterocyclic templates in the discovery of biologically active 
compounds. 
3. Experimental 
3.1 Instrumentation and general methods 
NMR spectra were recorded on a Bruker Spectrospin spectrometer operating at 400 MHz for 
1H spectra and 100 MHz for 13C spectra.  The following abbreviations were used: s = singlet, 
d = doublet, t = triplet, m = multiplet, br = broad.  Coupling constants (J) are quoted in Hz.  
Chemical shifts are reported as ppm relative to the residual protio solvent resonance.    spectra 
were determined using a Mattson 1000 FT spectrometer or a Nicolet Impact 400D FT 
spectrometer as a KBr disc. Mass spectra were measured on a JEOL JMS AX505 
spectrometer at the University of Strathclyde using electrospray (ES), or chemical ionisation 
(CI) methods.  Accurate mass were recorded at the University of Glasgow on Jeol JMS-7 
MStation high resolution magnetic sector using electron impact (EI) or fast atom 
bombardment (FAB) ionisation. Melting points, where measurable, were determined on a 
Reichert hot stage apparatus and are uncorrected.  Microanalysis is typically unreliable in 
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polyazabicyclic compounds due to poor combustion even in the presence of a catalyst (WO3); 
microanalytical data is reported where satisfactory and 400 MHz 1H NMR spectra are 
included in the Electronic Supplementary Information†.  TLC was carried out on silica 
(Merck 0.25 mm 60 F254) visualising the plates with either aqueous potassium permanganate 
solution or UV; whilst suitable for monitoring reactions and product purity, with these highly 
polar compounds, Rf values vary from run to run and have therefore not been given.  Column 
chromatography was carried out using silica gel (230–400 mesh; 40–60 mm).  All reagents 
were bought from Aldrich (Gillingham, Dorset, U.K.).   Microwave reactions were carried out 
on a Biotage Initiator 2.0. HPLC was carried out on a Waters machine equipped with a 1525 
binary HPLC pump, Waters 2487 dual λ absorbance detector, and Breeze software using 
Vydac protein and peptide C18 column, λ = 254 nm. Gradient elution was with 
water/acetonitrile with or without trifluoroacetic acid.  
 
3.2 Experimental procedures 
 
3.2.1 6-Amino-2-(benzylthio)pyrimidin-4(3H)-one 119 was prepared as previously 
described. 
  
3.2.2 6-(Allyloxy)-2-(benzylthio)-pyrimidin-4-amine 2 and 3-allyl-6-amino-2-(benzylthio) 
pyrimidin-4(3H)-one 3: 
To 6-amino-2-(benzylsulfanyl)pyrimidin-4(3H)-one 1 (1.790 g, 7.67 mmol) in anhydrous 
DMF (20 mL) was added allyl bromide (700 µl, 0.980 g, 8.03 mmol, 1.05 eq.) and potassium 
carbonate (1.24 g, 8.98 mmol, 1.17 eq.).  The reaction mixture was left stirring at 100 °C for 
20 h.  The reaction mixture was cooled to room temperature, filtered under vacuum and the 
solvent evaporated under reduced pressure.  The residue was dissolved in water (20 mL) and 
extracted with DCM (50 mL).  The organic layers were combined, dried over MgSO4 and 
concentrated under reduced pressure to give a pale yellow solid.  The crude product was 
purified by column chromatography using ethyl acetate (100%) as eluant to give 6-(allyloxy)-
2-(benzylthio)-pyrimidin-4-amine 2 as a pale yellow crystalline solid (0.924 g, 3.38 mmol, 
62%) and 3-allyl-6-amino-2-(benzylthio)pyrimidin-4(3H)-one 3 as a white crystalline solid 
(0.127 g, 0.464 mmol, 9%). 
Characterisation of 2:  m.p. 80 – 82 °C; νmax (KBr): 3477, 3302, 3143, 1642, 1549, 1469, 
1430, 1336, 1205, 984, 933, 815, 716, 696, 592 cm-1; δH (DMSO-d6): 4.30 (2H, s, CH2S), 
4.73 (2H, d, J = 5.6 Hz, CH2O), 5.20 (1H, d, J = 10.8 Hz, CH=CH2), 5.33 (1H, d, J = 16.0 Hz, 
CH=CHH), 5.45 (1H, s, H-5), 5.94 – 6.04 (1H, m, CH=CH2), 6.75 (2H, br s, NH2), 7.21 – 
7.31 (3H, m, C6H5), 7.39 – 7.41 (2H, m, C6H5); δC (DMSO-d6): 33.8, 66.0, 81.9, 117.4, 126.9, 
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128.3, 128.8, 133.6, 138.6, 165.2, 168.3, 168.8.  HRMS (EI):  M+, found 273.0936. 
C14H15N3OS requires 273.0936.  
Characterisation of 3:  m.p. 167 – 174 °C (slow decomposition).  νmax (KBr): 3391, 3316, 
3186, 1644, 1620, 1508, 1453, 1424, 1289, 1253, 1197, 1127, 1025, 913, 800, 635 cm-1; δH 
(DMSO-d6): 4.39 (2H, s, CH2N), 4.45 (2H, s, CH2S), 4.94 (1H, s, H-5), 5.01 (1H,  d, J = 17.6 
Hz, CH=CHH), 5.12 (1H, d, J = 10.4 Hz, CH=CH2), 5.70 – 5.80 (1H, m, CH=CH2), 6.57 (2H, 
br s, NH2), 7.24 – 7.33 (3H, m, C6H5), 7.44 – 7.46 (2H, m, C6H5);  δC (DMSO-d6): 35.1, 44.3, 
80.7, 116.8, 127.4, 128.4, 129.3, 132.1, 137.0, 160.5, 161.2 (x2).  HRMS (EI):  M+, found 
273.0936. C14H15N3OS requires 273.0936. 
 
3.2.3 5-Allyl-6-amino-2-(benzylthio)-4(3H)-pyrimidinone 4 
6-(Allyloxy)-2-(benzylsulfanyl)-4-pyrimidinylamine 2 (0.310 g, 1.13 mmol) was heated to 
200 °C under nitrogen for 24 h using a sand bath.  The resulting brown solid was dissolved in 
methanol (15 mL) and filtered. The excess solvent was removed under reduced pressure and 
the resulting solid was purified by flash chromatography to yield the title compound 4 as a 
white solid (0.290 g, 1.06 mmol, 92%), m.p. 152 – 154 oC. νmax (KBr): 3400, 3925, 1625, 
1610, 1582, 1470, 1410, 1305, 1206, 1046, 934, 815, 717, 637, 593 cm-1; δH (DMSO-d6):  
2.50 (2H, d, J = 8.0 Hz, CH2CH=), 4.72 (2H, s, CH2S), 4.94 (1H, d, J = 10.4 Hz, CH=CH2), 
5.05 (1H, d, J = 16.0 Hz, CH=CH2), 5.67 – 5.89 (1H, m, CH=CH2), 6.26 (2H, br s, NH2), 7.18 
– 7.30 (3H, m, C6H5), 7.37 – 7.47 (2H, m, C6H5), 11.66 (1H, br s, NH);  δC (DMSO-d6):  26.4, 
33.1, 90.6, 114.2, 127.1, 128.3, 129.1, 135.4, 137.9.  HRMS (EI):  M+, found 273.0939. 
C14H15N3OS requires 273.0936. 
 
3.2.4 Ethyl 2-[(4-amino-2-(benzylsulfanyl)-6-{[2-(ethoxycarbonyl)-2-propenyl]oxy}5-
pyrimidinyl)methyl]acrylate 5 
6-Amino-2-(benzylthio)pyrimidin-4(3H)-one 1 (0.690 g, 2.95 mmol) was dissolved in DMF 
(12 mL, anhydrous) at room temperature under nitrogen.  Ethyl 2-(bromomethyl)acrylate 
(610 µl, 4.40 mmol, 1.50 eq.) and potassium carbonate (0.500 g, 3.62 mmol, 1.23 eq.) were 
added and the reaction mixture was stirred at 55 °C for 24 h.  Once the reaction was complete 
(confirmed by TLC), the mixture was cooled to room temperature and the solvent evaporated 
under reduced pressure.  The subsequent yellow oil was dissolved in DCM, the organics were 
extracted with brine and dried over MgSO4 and concentrated under reduced pressure to give a 
yellow oil.  Purification of the crude product was achieved using column chromatography 
using ethyl acetate:hexane (1:1) as eluant.  The title compound 5 was isolated as a white solid 
(0.114 g, 0.249 mmol, 8%), m.p. 110 – 112 °C. νmax (KBr):  3407, 3323, 3191, 2991, 1707, 
1652, 1572, 1493, 1474, 1444, 1401, 1376, 1316, 1264, 1158, 1050, 956, 855, 776, 563 cm-1; 
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δH (DMSO-d6):  1.15 – 1.26 (6H, m, CH3 x 2), 3.33 (2H, s, CH2=C(CO2Et)CH2), 4.09 – 4.20 
(4H, m,  CH2 x 2), 4.29 (2H, s, CH2S), 4.98 (2H, s, CH2O), 5.14 (1H, s, =CHH), 5.75 (1H, s, 
=CHH), 5.99 (1H, s, =CHH), 6.19 (1H, s, =CHH), 6.19 (2H, br s, NH2), 7.19 – 7.31 (3H, m, 
C6H5), 7.39-7.41 (2H, m, C6H5); δC (DMSO-d6):  13.9, 14.0, 24.4, 33.8, 60.3, 60.5, 63.5, 90.7, 
123.1, 126.1, 126.8, 128.3, 128.8, 136.3, 137.0, 138.7, 163.4, 164.8, 165.4, 166.2, 166.2, 
166.4.  HRMS (ES): M+H+, found 458.1650. C23H27N3O5S requires 458.1671. 
 
3.2.5 Ethyl 2-{[4-amino-2-(benzylsulfanyl)-1,6-dihydro-6-oxopyrimidin-5-yl)methyl} 
acrylate 6a  
6-Amino-2-(benzylthio)pyrimidin-4(3H)-one 1 (0.520 g, 2.22 mmol) was dissolved in 
DMF (10 mL, anhydrous) to which ethyl 2-(bromomethyl)acrylate (310 µl, 2.24 mmol) 
was added.  The reaction mixture was then stirred under nitrogen for 7 d at room 
temperature prior to the concentration of excess solvent under reduced pressure.   The 
resulting residue was purified by flash column chromatography using hexane/ethyl 
acetate (2:1) as eluant.  The title compound 6a was obtained as a white crystalline solid 
(0.340 g, 0.998 mmol, 44%), m.p. 160 – 162 oC. νmax (KBr): 3483, 3368, 1693, 1614, 
1475, 1438, 1333, 11260, 1187, 1152, 1029, 953, 693 cm-1; δH (DMSO-d6): 1.27 (3H, t, J 
= 7.6 Hz, CH3), 3.18 (2H, s, CH2C=), 4.19 (2H, q, J = 7.6 Hz. CH2CH3), 4.34 (2H, s, 
CH2S), 5.22 (1H, s, C=CH2), 5.97 (1H, s, C=CH2), 6.34 (2H, br s, NH2), 7.21 – 7.34  (3H, 
m, C6H5), 7.43 – 7.46 (2H, m, C6H5), 11.70 (1H, br s, NH); δC (DMSO-d6): 14.1, 24.7, 
33.1, 60.2, 89.2, 122.7, 127.1, 128.4, 129.2, 137.3, 137.8, 160.4, 163.0, 166.8 (x 2). 
HRMS (EI): M+, found 345.1149. C17H19N3O3S requires 345.1147. 
 
Similarly prepared were: 
3.2.6 2-{[4-Amino-2-(benzylsulfanyl)-6-oxo-1,6-dihydro-5-pyrimidinyl]methyl}acrylic 
acid 6b 
From 6-amino-2-(benzylthio)pyrimidin-4(3H)-one 1 and 2-(bromomethyl)acrylic acid using 2 
eq. of the latter added over 2 d and a further 5 d reaction  in 30% yield, m.p. 157 – 159 °C. 
νmax (KBr): 3444, 3003, 1705, 1642, 1552, 1320, 1207, 1017, 929, 843, 710 cm-1; δH (DMSO-
d6): 3.07 (2H, s, CH2-C=), 4.31 (2H, s, CH2S), 5.91 (1H, br s, C=CH2), 6.33 (1H, br s, 
C=CH2), 6.36 (2H, s, NH2), 7.20 – 7.40 (3H, m, C6H5), 7.41 – 7.53 (2H, m, C6H5), 12.01 (1H, 
br s, NH);  δC (DMSO-d6):  34.0, 79.6, 124.7, 128.1, 128.6, 129.5, 137.5, 138.7, 158.3, 164.6, 
166.2, 172.6. HRMS (EI):  M+, found 317.0831. C15H15N3O3S requires 317.0834. 
 
3.2.7 Ethyl 2-[(2,4-diamino-6-oxo-1,6-dihydro-5-pyrimidinyl) methyl] acrylate 6c 
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From 2,6-diamino-4(3H)-pyrimidinone 7a and ethyl 2-(bromomethyl)acrylate reacting for 3 d 
in 83% yield, m.p. 120 – 122 oC. νmax (KBr): 3455, 3341, 3176, 1698, 1629, 1500, 1446, 1372, 
1260, 1151, 1023, 779, 647 cm-1; δH (DMSO-d6): 1.24 (3H, t, J = 7.1 Hz, CH3), 3.05 (2H, s, 
CH2-C=), 4.14 (2H, q, J = 7.1 Hz, CH2CH3), 5.26 (1H, d, J = 1.7 Hz, CH2=), 5.67 (2H, s, 
NH2), 5.94 (1H, d, J = 1.7 Hz, CH2=), 6.02 (2H, br s, NH2), 9.86 (1H, br s, NH);  δC (DMSO-
d6): 14.2, 25.1, 60.2, 83.4, 122.6, 137.4, 152.3, 157.7, 161.8, 166.7.  HRMS (EI): M+, found 
238.1070. C10H14N4O3 requires 238.1066. 
 
3.2.8 2-((2,4-Diamino-1,6-dihydro-6-oxopyrimidin-5-yl)methyl)acrylic acid 6d 
From 2,6-diaminopyrimidin-4(3H)-one 7a and 2-(bromomethyl)acrylic acid using 2 eq of the 
latter added over 2 d and a further 5 d reaction in  53 % yield, m.p. >230 °C.  νmax (KBr):  
3378, 3199, 2972, 2758, 1707, 1647, 1604, 1511, 1419, 1282, 1237, 1193, 1116, 1091, 958, 
808, 617, 550 cm-1; δH (DMSO-d6):  2.45 (2H, s, CH2-C=), 5.28 (1H, s, C=CH2), 5.90 (1H, s, 
C=CH2), 6.13 (2H, br s, NH2), 7.08 (2H, br s, NH2), 10.94 (1H, br s, NH), 11.22 (1H, br s, 
CO2H); δC (DMSO-d6):  24.2, 84.3, 122.7, 138.1, 152.0, 162.1, 162.3, 168.5.  HRMS (EI): 
M+, found 211.0832. C8H10N4O3 requires 211.0831. 
 
3.2.9 Ethyl 2-{[2-(benzylsulfanyl)-4-(methylamino)-6-oxo-1,6-dihydro-5-
pyrimidinyl]methyl}acrylate 6e 
From 2-(benzylsulfanyl)-6-(methylamino)-4(3H)-pyrimidinone 7b and ethyl 2-
(bromomethyl)acrylate with a reaction time of 4 d in 33% yield, m.p. 171 – 173 oC. νmax 
(KBr): 3503, 3367, 1670, 1618, 1483, 1452, 1370, 1181, 707 cm-1; δH (CDCl3): 1.24 (3H, t, J 
= 7.1 Hz, CH3), 2.93 (3H, s,  NHCH3), 3.26 (2H, s, CH2C=), 4.14 (2H, q, J = 7.1 Hz, 
CH2CH3), 4.36 (2H, s, CH2S), 5.85 (1H, d, J = 1.4 Hz, CH2=), 5.95 (1H, d, J = 1.4 Hz, CH2=), 
6.12 (1H, m, NH), 7.18 – 7.33 (5H, m, C6H5), 12.48 (1H, br s, NH); δC (CDCl3): 14.2, 24.5, 
28.7, 34.5, 61.1, 92.7, 127.4, 127.7, 128.6, 128.9, 137.0, 137.6, 158.2, 160.1, 164.2, 169.0.  
HRMS (EI): M+, found 359.1303. requires C18H21N3O3S 359.1304.   
 
3.2.10 Ethyl 2-{[4-(benzylamino)-2-(benzylsulfanyl)-6-oxo-1,6-dihydro-5-
pyrimidinyl]methyl}acrylate 6f 
From 2-(benzylsulfanyl)-6-(benzylamino)-4(3H)-pyrimidinone 7c  and ethyl 2-
(bromomethyl)acrylate with 4 reaction in 33% yield, m.p. 168 – 171°C.  νmax (KBr): 3478, 
3165, 1774, 1661, 1559, 1534, 1459, 1205, 986 cm-1; δH (CDCl3): 1.32 (3H, t, J = 7.1 Hz, 
CH3), 3.35 (2H, s, CH2-C=), 4.11 (2H, q, J = 7.1 Hz, CH2CH3), 4.25 (2H, d, J = 5.5 Hz, 
CH2NH), 4.45 (3H, s, CH2S), 5.95 (1H, d, J = 1.5 Hz, CH2=), 6.04 (1H, d, J = 1.5 Hz, CH2=), 
6.15 (1H, t, J = 5.5 Hz, NHCH2), 7.47 – 7.22 (10H, m, 2 x C6H5), 12.96 (1H, br s, NH).  
HRMS (FAB): M++H, found 436.1694. C24H25N3O3S requires 436.1695. 
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3.2.11 Ethyl 2-{[4-(allylamino)-2-(benzylsulfanyl)-6-oxo-1,6-dihydro-5-pyrimidinyl] 
methyl} acrylate 6g  as a pale yellow solid in 33% yield, mp 165 – 168 °C. νmax (KBr): 3503, 
3367, 1670, 1618, 1483, 1452, 1370, 1181, 707 cm-1; δH (CDCl3): 1.31 (3H, t, J = 7.1 Hz, 
CH3), 3.37 (2H, s, CH2-C=), 4.08 – 4.12 (2H, m, CH2NH), 4.22 (2H, q, J = 7.1 Hz, CH2CH3), 
4.40 (2H, s, CH2S), 5.12 (1H, d, J = 1.5 Hz, CH2= ), 5.16 (1H, d J = 1.5 Hz, CH2=), 5.85 – 
5.94 (1H, m, CH=CH2), 6.04 (1H, d, J = 1.6 Hz, CH=CHH), 6.09 (1H, t, J = 5.7 Hz, NHCH2), 
6.21 (1H, d, J = 16 Hz, CH=CHH), 7.24 – 7.42 (5H, m, C6H5), 13.04 (1H, s, NH);  δC 
(CDCl3): 13.2, 23.4, 33.5, 43.0, 60.1, 91.9, 114.5, 126.4, 126.7, 127.6, 127.9, 134.4, 135.8, 
136.5, 157.3, 158.3, 163.5, 167.9.  HRMS (FAB): M++H, found 386.1534. C20H23N3O3S 
requires 386.1538. 
  
3.2.12 2-(Benzylsulfanyl)-6-(methylamino)-4(3H)-pyrimidinone 7b 
2-(Benzylsulfanyl)-6-chloro-4(3H)-pyrimidinone (500 mg, 1.98 mmol) was dissolved in 2.0 
M methylamine solution in THF (4.95 mL, 5 eq). The solution was heated to 80 °C in a 
sealed tube and stirred for 48 hours. The excess solvent was removed under reduced pressure 
and the residue was taken up in ethyl acetate. The solvent layer was washed with water (2 x 
15 mL) and then saturated aqueous sodium bicarbonate solution (15 mL). The organic layer 
was then dried over MgSO4. The solvent was removed under reduced pressure and the residue 
was purified by flash chromatography to yield the title product as a fine white powder (186 
mg, 0.0752 mmol, 38%), m.p: >230 oC. νmax (KBr): 3214, 3059, 1637, 1618, 1421, 1302, 
1256, 1207, 1097, 978, 792, 711, 570 cm-1. δH (DMSO-d6): 2.77 (3H, s, CH3), 4.35 (2H, s, 
CH2S), 4.81 (1H, s, H-5), 6.96 (1H, bd, -NHCH3), 7.23 – 7.44 (5H, m, C6H5), 11.55 (1H, s, 
NH); δC (DMSO-d6): 27.8, 33.1, 127.1, 128.4, 129.0, 137.9, 162.8, 164.0. HRMS (EI): M+, 
found 247.0776. C12H13N3OS requires 247.0779.  
 
Similarly prepared were: 
3.2.13 6-(Benzylamino)-2-(benzylsulfanyl)-4(3H)-pyrimidinone 7c as a white solid in 38% 
yield, m.p: 230 oC. νmax (KBr): 3450, 3000, 2906, 2818, 1884, 1807, 1650, 1554, 1466, 1351, 
1222, 1097, 984, 937, 829, 712, 552 cm-1 δH (DMSO-d6): 4.14 (2H, s, CH2N), 4.47 (2H, s, 
CH2S), 4.90 (1H, s, H-5) 7.22 – 7.45 (11H, m, C6H5 x 2 and NHCH2), 11.54 (1H, s, NH); δC 
(DMSO-d6): 34.3, 44.5, 126.8, 127.0, 127.1, 127.9, 128.3, 137.6, 138.2, 159.3, 162.4, 163.8. 
HRMS (FAB): M++H, found 324.1174. C18H17N3OS requires 324.1171  
 
3.2.14 6-(Allylamino)-2-(benzylsulfanyl)-4(3H)-pyrimidinone 7d as a white solid in 37% 
yield, m.p: >230 oC;   νmax (KBr): 3214, 3059, 1637, 1618, 1421, 1302, 1256, 1207, 1097, 978, 
792, 711, 570 cm-1; δH (DMSO-d6): 3.88 (2H, m, -NH-CH2), 4.34 (2H, s, CH2S), 4.89 (1H, s, 
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H-5), 5.10 (1H, d, J = 1.5, -CH2-CH=CH2), 5.17 (1H, d, J = 17.5, -CH2-CH=CH2), 5.80 (1H, 
m , -CH2-CH=CH2), 7.21 (1H, br s, NH) 7.42 – 7.23 (5H, m, C6H5), 11.54 (1H, s, -NH); δC 
(DMSO-d6): 33.2, 42.4, 115.4, 115.6, 127.1, 128.4, 129.0, 134.4, 137.9, 159.2, 162.2, 163.3. 
 
3.2.15 2-(Benzylsulfanyl)-6-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 8a 
Ethyl 2-{[4-amino-2-(benzylsulfanyl)-6-oxo-1,6-dihydro-5-pyrimidinyl]methyl}acrylate 6a 
(0.100 g, 0.289 mmol) was dissolved in DMF (3 mL, anhydrous) to which 1,3,4,6,7,8-
hexahydro-2H-pyrimido[1,2-a]pyrimidine (0.089 g, 0.597 mmol, 2.2 eq.) was added.  The 
reaction solution was then irradiated in the microwave apparatus at 100 °C for 30 min. The 
excess solvent was removed under reduced pressure and the resulting residue was dissolved 
in de-ionised water (10 mL).  The reaction solution was adjusted to pH 6-7 using dil. acetic 
acid, which caused a white precipitate to form.  The precipitate was filtered off and washed 
with ether (2 x 10 mL) to yield the title compound 8a as a white solid (0.085 g, 0.0283 mmol, 
98%), m.p. > 230 oC. νmax (KBr): 3450, 3027, 2890, 1953, 1807, 1626, 1590, 1394, 1271, 959, 
922, 790, 719, 571 cm-1; δH (DMSO-d6): 2.01 (3H, s, CH3), 4.43 (2H, s, CH2S), 7.23 – 7.33 
(3H, m, C6H5), 7.53 – 7.67 (2H, m, C6H5), 7.68 (1H, s, H-5), 12.27 (1H, br s NH), 12.73 (1H, 
br s, NH); δC (TFA): 14.1, 35.3, 102.9, 127.3, 127.8, 128.4, 128.7, 134.2, 137.6, 151.5, 164.2, 
166.5. HRMS (FAB): M++H, found 300.0816. C15H14N3O2S requires 300.0807.   
 
Similarly prepared were: 
3.2.16 2-Amino-6-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 8b as a highly 
insoluble beige solid in 81% yield, m.p. > 230 oC. .νmax (KBr): 3443, 3413, 3141, 1698, 1673, 
1458, 1351, 1112, 841. δH (TFA): 2.32 (3H, s, CH3), 8.12 (1H, s, H-5);  δC (TFA): 16.4, 
100.2, 130.1, 138.6, 145.5, 153.3, 161.3, 167.8. 
 
3.2.17 2-(Benzylsulfanyl)-6,8-dimethylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 8c as a 
white solid in 96% yield, m.p.  >230 oC. νmax (KBr): 2854, 1642, 1537, 1492, 1453, 1281, 
1152, 988, 789, 701, 570 cm-1; δH (DMSO-d6): 2.06 (3H, s, CCH3), 3.62 (3H, s, NCH3), 4.53 
(2H, s, CH2S), 7.26 – 7.48 (5H, m, C6H5), 7.74 (1H, s, H-5), 12.97 (1H, s, NH); δC (DMSO-
d6): 14.1, 35.3, 102.9, 127.3, 127.8, 128.4, 128.7, 134.2, 137.6, 151.5, 164.2, 166.5.  HRMS 
(FAB): M++H, found 314.0962. C16H16N3O2S requires 314.0963.   
 
3.2.18 8-Benzyl-2-(benzylsulfanyl)-6-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 
8d as a white solid in 96% yield, m.p.  > 230 oC. νmax (KBr): 3452, 3183, 1642, 1629, 1588, 
1465, 1264, 1098, 964, 951 δH (DMSO-d6):  2.01 (3H, s, CH3), 4.48 (2H, s, CH2S), 5.35 (2H, 
s, CH2N), 7.21 – 7.36 (10H, m, C6H5 x 2), 7.71 (1H, s, H-5), 12.98 (1H, s, NH); δC (DMSO-
d6): 16.6, 33.8, 43.9, 99.4, 120.6, 127.0, 127.3, 127.6, 128.0, 128.1, 128.3, 132.7, 138.1, 
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152.2, 160.8, 161.1, 165.3. HRMS (FAB): M++H found 390.1276. C22H19N3O2S requires 
390.1276.   
 
3.2.19 8-Allyl-2-(benzylsulfanyl)-6-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 8e 
as a white solid in 96% yield, m.p.  > 230 oC.  νmax (KBr): 2854, 1642, 1537, 1492, 1453, 
1281, 1152, 988, 789, 701, 570 cm-1; δH (DMSO-d6): 2.00 (3H, s, CH3), 4.47 (2H, s, CH2S), 
4.91 (2H, d, J = 2.1 Hz, CH2-CH=), 4.95 (1H, dd, J = 17.2, 1.6  Hz, CH=CHH), 5.07 (1H, dd, 
J = 10.3, 1.6  Hz, CH=CHH), 5.86 – 5.93 (1H, m, CH=CH2), 7.25 – 7.42 (5H, m, C6H5), 7.75 
(1H, s, H-5), 12.99 (1H, s, NH); δC (DMSO-d6): 16.8, 33.8, 43.4, 99.8, 116.3, 125.1, 127.4, 
128.6, 128.8, 131.3, 133.0, 136.8, 151.8, 160.5, 161.3, 162.2. HRMS (FAB): M++H, found 
340.1119. C18H17N3O2S requires 340.1120.  
 
3.2.20 3-({[6-Amino-2-(benzylsulfanyl)-4-pyrimidinyl]oxy}methyl)-4-phenyl-3-buten-2-
one 10a 
6-Amino-2-(benzylsulfanyl)pyrimidin-4(3H)-one 1 (0.250 g, 1.07 mmol) was dissolved in 
DMF (15 mL, anhydrous) to which cesium carbonate (0.348 g, 1.07 mmol, 1.0 eq.), 3-
(chloromethyl)-4-phenyl-3-buten-2-one15 (0.250 g, 1.28 mmol, 1.2 eq.) and potassium iodide 
(0.035 g, 0.214 mmol, 0.2 eq.) was added.  The reaction mixture was stirred at room 
temperature for 24 h.  The reaction mixture was then filtered and partitioned between water 
and ethyl acetate.  The ethyl acetate layer was then dried over MgSO4, the solvent was 
removed under reduced pressure and the residue was purified by flash column 
chromatography to yield the title compound 10a as a pale yellow solid (0.273 g, 0.70 mmol, 
65%), m.p. 146 – 148 oC.  νmax (KBr): 3476, 3350, 3230, 1964, 1643, 1626, 1514, 1425, 1396, 
1300, 1270, 1196, 1035, 803, 759, 700 cm-1; δH (CDCl3): 2.49 (3H, s, CH3), 4.32 (2H, s, 
CH2S), 4.67 (2H, br s, NH2), 5.15 (2H, s, OCH2), 5.53 (1H, s, H-5), 7.17 – 7.44 (10H, m, 
C6H5 x 2), 7.82 (1H, s, C=CH); δC (CDCl3): 27.0, 34.7, 60.4, 82.8, 135.3, 136.0, 139.5, 146.0, 
166.1, 169.2, 169.7, 199.4.  HRMS (EI): M+, found 391.1356. C22H21N3O2S requires 
391.1354. 
 
3.2.21 3-({[6-Amino-2-(benzylsulfanyl)-4-pyrimidinyl]oxy}methyl)-4-[4-
(trifluoromethyl)phenyl]-3-buten-2-one 10b 
6-Amino 2-(benzylsulfanyl)pyrimidin-4(3H)-one 1 (250 mg, 1.07 mmol) was dissolved in 
DMF (15 mL, anhydrous) to which cesium carbonate (0.348 g, 1.07 mmol, 1.0 eq.), 3-
(chloromethyl)-4-(4-trifluoromethylphenyl)-3-buten-2-one15 (0.267 g, 1.28 mmol, 1.2 eq.) 
and potassium iodide (0.035 g, 0.214 mmol, 0.2 eq.) was added.  The reaction mixture was 
stirred at room temperature for 24 h.  The reaction mixture was then filtered and partitioned 
between water and ethyl acetate.  The ethyl acetate layer was dried over MgSO4, the solvent 
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was removed under reduced pressure and the residue was purified by flash column 
chromatography to yield the title compound 10b as a white powder (0.340 g, 0.074 mmol, 
69%), m.p. 145 – 147 °C.  νmax (KBr): 3477, 3366, 1651, 1625, 1578, 1454, 1424, 1325, 1300, 
1195, 1123, 1069, 704 cm-1; δH (CDCl3): 2.50 (3H, s, CH3) 4.31 (2H, s, CH2S), 4.72 (2H, br s, 
NH2), 5.10 (2H, s, OCH2), 5.51 (1H, s, H-5), 7.18 – 7.66 (9H, m, C6H5 and C6H4), 7.78 (1H, 
s, C=CH); δC (CDCl3): 26.4, 35.0, 60.1, 83.4, 125.7, 125.7 (CF3), 127.0, 128.3, 128.8, 129.7, 
137.5, 137.9, 138.0, 142.5, 164.1, 169.0, 170.5, 198.2. HRMS (EI): M+, found 459.1232. 
C23H20F3N3O2S requires 459.1228.  
 
3.2.22 6-Benzyl-2-(benzylsulfanyl)-7-methylpyrido[2,3-d]pyrimidin-4(3H)-one 
trifluoroacetate salt 11a   
3-({[6-Amino-2-(benzylsulfanyl)-4-pyrimidinyl]oxy}methyl)-4-phenyl-3-buten-2-one 10a 
(0.250 g, 0.639 mmol) was dissolved in THF (20 mL, anhydrous) to which titanium 
tetrachloride complex 1:2 THF (0.021 g, 0.0628 mmol) was added.  The reaction was 
refluxed for 3 d under nitrogen.  The excess solvent was removed under reduced pressure and 
the resulting residue was washed with saturated aqueous NaHCO3 solution (2 x 10 mL) and 
de-ionised water (2 x 10 mL).  The organic layer was dried over MgSO4, filtered under 
reduced pressure and the solvent was removed under reduced pressure.  The resulting residue 
was purified by HPLC to yield the title compound 11a as a white solid (0.042 g, 0.112 mmol, 
18%), m.p. 181 – 183 °C. νmax (KBr): 3437, 1709, 1662, 1638, 1541, 1186, 797, 700 cm-1; δH 
(CDCl3): 2.65 (3H, s, CH3), 4.12 (2H, s, CCH2), 4.68 (2H, s, SCH2) 7.53 - 7.12 (10H, m, C6H5 
x 2), 8.23 (1H, s, H-5), 10.00 (1H, s, NH); δC (CDCl3): 19.9, 35.7, 37.7, 114.4, 127.4, 127.9, 
128.6, 128.6, 129.3, 129.3, 134.3, 135.1, 136.5, 141.2, 152.8, 160.1, 162.3, 165.5. HRMS 
(EI): M+, found 374.1330. C22H20N3OS requires 374.1327.  
 
3.2.23 2-(Benzylsulfanyl)-7-methyl-6-[4-(trifluoromethyl)benzyl] pyrido[2,3-
d]pyrimidin-4(3H)-one 11b 
3-({[6-Amino-2-(benzylsulfanyl)-4-pyrimidinyl]oxy}methyl)-4-[4-(trifluoromethyl) phenyl]-
3-buten-2-one 10b (0.250 g, 0.544 mmol) was dissolved in THF (20 mL, anhydrous) to which 
titanium tetrachloride complex 1:2 THF (0.018 g, 0.054 mmol) was added.  The reaction was 
refluxed for 3 d under nitrogen.  The excess solvent was removed under reduced pressure and 
was washed with saturated aqueous NaHCO3 solution.  The reaction mixture was filtered and 
partitioned between water and ethyl acetate.  The ethyl acetate layer was dried over MgSO4, 
filtered under reduced pressure and the solvent was removed under reduced pressure.  The 
title compound 11b was re-crystallised from methanol as a white solid (0.055 g, 0.0125 
mmol, 23%), m.p. 195 – 198 °C. νmax (KBr): 3027, 2922, 1682, 1570, 1411, 1325, 1164, 1066, 
805, 699 cm-1; δH (CDCl3): 2.63 (3H, s, CH3), 4.15 (2H, s, CH2C), 4.68 (2H, s, CH2S), 7.23 – 
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7.58 (9H, m, C6H5 and C6H4), 8.26 (1H, s, H-5), 11.57 (1H, s, NH); δC (CDCl3): 23.7, 35.5, 
38.4, 113.2, 125.4, 125.8, 127.9, 128.8, 128.9, 129.3, 128.8, 132.1, 136.6, 142.4, 157.2, 
159.0, 163.2, 166.0.  HRMS (EI): M+, found 441.1126. C23H18F3N3OS requires 441.1123. 
 
3.2.24 8-Benzyl-2-(benzylamino)-6-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 13a 
8-Benzyl-2-(benzylsulfanyl)-6-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 8d (0.050  
g, 0.128 mmol) was dissolved in DMF (3 mL, anhydrous) to which m-CPBA (0.066 g, 0.39 
mmol, 3 eq.) was added and the mixture was stirred under nitrogen for 3 h at room 
temperature.  The excess solvent was removed under reduced pressure and the residue was 
dissolved in benzylamine (2.0 mL, 18.31 mmol) and heated in the microwave at 110 °C for 1 
h.  The excess solvent was removed under reduced pressure and the resulting residue was 
purified by flash chromatography to yield the title compound 13a as a pale yellow solid 
(0.033 g, 0.088 mmol, 68%), m.p. > 230 °C. νmax (KBr): 3351, 3316, 2987, 1677, 1648, 1589, 
1176, 1049, 949 cm-1; δH (DMSO-d6): 2.00 (3H, s, CH3), 4.51 (2H, d, J = 5.5 Hz, NHCH2), 
5.37 (2H, s, NCH2), 7.18 – 7.24 (10H, m, C6H5 x 2), 7.18-7.24 (1H, m, NH), 7.66 (1H, s, H-
5), 11.44 (1H, s, NH); δC (DMSO-d6): 14.5, 43.7, 44.0, 95.7, 120.1, 126.7, 126.9, 127.2, 
127.6, 128.1, 132.0, 137.8, 138.9, 153.4, 154.6, 161.0, 163.1.  HRMS (FAB): M++H, found 
373.1662. C22H20N4O2 requires 373.1665. 
 
Similarly prepared were: 
3.2.25 8-Benzyl-6-methyl-2-(1-pyrrolidinyl)pyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 
13b as a beige solid in 59% yield, m.p. > 230 °C. νmax (KBr):  3342, 2987, 2852, 1668, 1652, 
1441, 1216, 1062, 925 cm-1; δH (DMSO-d6): 1.89 (4H, s, CH2CH2), 2.01 (3H, s, CH3), 3.46 
(4H, s, CH2N x 2), 5.37 (2H, s, CH2N), 7.18-7.33 (5H, m, C6H5), 7.67 (1H, s, H-5), 11.16 
(1H, s, NH); δC (DMSO-d6): 16.6, 24.7, 44.0, 46.2, 94.6, 119.6, 126.8, 127.8, 128.1, 132.2, 
138.1, 150.7, 154.3, 161.1, 163.3. HRMS (FAB): M++H, found 337.1667. C19H20N4O2 
requires 367.1659. 
 
3.2.26 8-Allyl-2-(benzylamino)-6-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 13c 
as a beige solid in 62% yield, m.p. > 230 °C. δH (DMSO-d6): 1.98 (3H, s, CH3), 4.53 (2H, d, J 
= 5.9, CH2NH), 4.75 (2H, d, J = 5.9, CH2-CH=), 4.94 (1H, dd, J = 17.2, 1.5 Hz, CH=CHH), 
4.95 (1H, dd, J  = 10.3, 1.5 Hz, CH=CHH), 5.75 – 5.84 (1H, m, CH=CH2), 7.24 -7.34 (5H, m, 
C6H5), 7.63 (1H, s, H-5), 11.11 (1H, s, NH); δC (DMSO-d6): 16.5, 43.1, 43.9, 95.5, 116.6, 
120.2, 127.0, 128.3, 131.7, 133.0, 138.8, 152.8, 154.3, 160.3, 162.7. HRMS (FAB): M++H 
found 323.1510. C18H18N4O2 requires 323.1508.  
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3.2.27 8-Allyl-6-methyl-2-(1-pyrrolidinyl)pyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 13d 
as a beige solid 64% yield, m.p. > 230 °C. νmax (KBr): 3161, 2962, 1683, 1652, 1605, 1547, 
1524, 1378, 1205, 986 cm-1; δH (DMSO-d6): 1.92 (4H, t, J = 6.8 Hz, CH2CH2), 1.99 (3H, d, J 
= 1.1 Hz, CH3), 3.50 (4H, t, J = 6.8 Hz, CH2N x 2), 4.81 (2H, dd, J = 7.0, 1.4 Hz, CH2-CH=), 
5.06 (1H, t, J = 1.5 Hz, CH=CHH), 5.09 (1H, dd,  J =  12.0, 1.5 Hz, CH=CHH), 5.85 – 5.95 
(1H, m, CH=CH2), 7.63 (1H, d, J = 1.1 Hz, H-5), 11.02 (1H, s, NH);  δC (DMSO-d6): 16.5, 
24.7, 43.0, 46.8, 95.4, 116.8, 119.5, 132.0, 133.1, 150.6, 154.1, 161.1, 162.9.  HRMS (FAB): 
M++H found 287.1505. C15H18N4O2 requires 287.1508.  
 
3.2.28 2-(Benzylamino)-7-methyl-6-[4-(trifluoromethyl)benzyl]pyrido[2,3-d]pyrimidin-
4(3H)-one 14a 
2-(Benzylsulfanyl)-7-methyl-6-[4-(trifluoromethyl)benzyl]pyrido [2,3-d]pyrimidin-4(3H)-one 
11b (0.050 g, 0.113 mmol) was dissolved in THF (3 mL, anhydrous) to which  m-CPBA 
(0.059 g, 0.342 mmol) was added.  The reaction mixture was stirred at room temperature for 3 
h under nitrogen.  The excess solvent was removed and the residue was dissolved in 
benzylamine (2 mL, 18.31 mmol) and the solution was heated in a microwave at 110 °C for 1 
h.  The excess solvent was removed under reduced pressure and the residue was dissolved in 
ethyl acetate (10 mL) and washed with saturated aqueous NaHCO3 solution (2 x 5 mL) and 
water (2 x 5 mL).  The organic layer way then dried over MgSO4 and was purified by HPLC 
to yield the title compound 14a as a white solid (0.021 g, 0.0495 mmol, 44%), m.p. 201-203 
°C.  νmax (KBr): 3335, 3193, 1672, 1561, 1523, 1493, 1351, 1292, 1131, 1039, 964 cm-1; δH 
(DMSO-d6): 2.54 (3H, s, CH3), 4.22 (2H, s, CH2C), 4.66 (2H, d, J = 5.8 Hz, CH2NH), 7.26 – 
7.70 (9H, m, C6H5 and C6H4), 8.01 (1H, s, H-5), 8.39 (1H, br s, NH), 11.96 (1H, s, NH); δC 
(DMSO-d6): 26.2, 35.6, 43.8, 99.5, 123.4, 125.5, 125.5, 127.2, 127.2, 128.5, 129.5, 130.4, 
138.2, 143.7, 154.3, 158.0, 158.2, 158.4, 172.9. HRMS (FAB): M++H, 425.1588. 
C23H19F3N4O requires 425.1589.  
 
3.2.29 7-Methyl-2-(1-pyrrolidinyl)-6-[4-(trifluoromethyl)benzyl] pyrido[2,3-d]pyrimidin-
4(3H)-one 14b 
2-(Benzylsulfanyl)-7-methyl-6-[4-(trifluoromethyl)benzyl]pyrido [2,3-d]pyrimidin-4(3H)-one 
11b (0.050 g, 0.113 mmol) was dissolved in THF (3 mL, anhydrous) to which  m-CPBA 
(0.059 g, 0.342 mmol) was added.  The reaction mixture was stirred at room temperature for 3 
h under nitrogen.  The excess solvent was removed and the residue was dissolved in 
pyrrolidine (2.0 mL, 23.96 mmol) and the solution was heated in a microwave at 110 °C for 1 
h.  The excess solvent was removed under reduced pressure and the residue was dissolved in 
ethyl acetate (10 mL) and washed with saturated aqueous NaHCO3 solution (2 x 5 mL) and 
water (2 x 5 mL).  The organic layer way then dried over MgSO4 and purified by HPLC to 
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yield the title compound 14b as a white solid (0.022 g, 0.0574 mmol, 51%), m.p. 205-207 °C.  
νmax (KBr):  3177, 3061, 1720, 1621, 1553, 1414, 1328, 1217, 1042, 921 cm-1; δH (DMSO-d6): 
1.90 (4H, t, J = 6.5 Hz, CH2CH2), 2.41 (3H, s, CH3), 3.50 (4H, t, J = 6.5 Hz, CH2N x 2), 4.12 
(2H, s, CH2C), 7.40 (2H, d, J = 8.1 Hz, 2,6-CH of Ar), 7.67 (2H, d, J = 8.1 Hz, 3,5-CH2 of 
Ar), 7.88 (1H, s, H-5), 11.20 (1H, s, NH); δC (DMSO-d6): 23.6, 25.4, 38.2, 47.0, 108.9, 125.6, 
127.6, 128.8, 129.0, 136.1, 143.1, 150.2, 159.6, 164.3, 165.7.  HRMS (FAB): M++H, found 
389.1584. C20H19F3N4O requires 389.1589.  
 
3.2.30 2-Anilino-7-methyl-6-[4-(trifluoromethyl)benzyl]pyrido[2,3-d]pyrimidin-4(3H)-
one trifluoroacetate salt 14c   
2-(Benzylsulfanyl)-7-methyl-6-[4-(trifluoromethyl)benzyl]pyrido[2,3-d]pyrimidin-4(3H)-one 
11b (0.050 g, 0.113 mmol)  was dissolved in THF (3 mL, anhydrous) to which m-CPBA 
(0.059 g, 0.342 mmol, 3 eq.) was added.  The reaction mixture was stirred at room 
temperature under nitrogen for 3 h.  Aniline (2.0 mL, 21.95 mmol) was then added to the 
solution and heated in the microwave at 110 °C for 1 h.  The excess solvent was removed 
under reduced pressure and the residue was dissolved in ethyl acetate (10 mL) and washed 
with saturated aqueous NaHCO3 solution (2 x 5 mL) and water (2 x 5mL).  The organic layer 
way then dried over MgSO4 and purified by HPLC to yield the title compound 14c as a white 
solid (0.017 g, 0.0414 mmol, 37%), m.p. 199 – 201 °C.  νmax (KBr): 3288, 3020, 2934, 1643, 
1578, 1462, 1381, 1320, 1215, 990, 739 cm-1; δH (DMSO-d6): 2.56 (3H, s, CH3), 4.22 (2H, s, 
CH2C), 7.14 – 7.23 (9H, m, C6H5 and C6H4), 8.37 (1H, s, H-5), 9.60 (1H, s, NH), 11.54 (1H, 
s, NH); δC (DMSO-d6): 20.1, 35.9, 100.0, 121.2, 123.4, 124.2, 125.2, 125.5, 127.1, 127.3, 
128.9, 129.3, 129.5, 137.6, 143.7, 151.5, 158.3, 158.5. HRMS (FAB): M++H, found 
411.1429. C22H17F3N4O requires 411.1433.  
 
3.2.31 7-Methyl-6-[4-(trifluoromethyl)benzyl]pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
trifluoroacetate salt 14d   
2-(Benzylsulfanyl)-7-methyl-6-[4-(trifluoromethyl)benzyl]pyrido[2,3-d]pyrimidin-4(3H)-one 
11b (0.050 g, 0.113 mmol)  was dissolved in THF (3 mL, anhydrous) to which m-CPBA 
(0.059 g, 0.342 mmol, 3 eq.) was added.  The reaction mixture was stirred under nitrogen for 
24 h at room temperature.  The excess solvent was removed under reduced pressure and the 
residue was dissolved in ethyl acetate (10 mL) and washed with saturated aqueous NaHCO3 
solution (2 x 5 mL) and water (2 x 5 mL).  The organic layer was then dried over MgSO4 and 
purified by HPLC to yield the title compound 14d as a white solid (0.018 mg, 0.0401 mmol, 
35%), m.p. 210 – 212 °C. νmax (KBr):  3318, 2931, 1661, 1621, 1567, 1506, 1465, 1298, 941, 
767 cm-1; δH (DMSO-d6): 2.43 (3H, s, CH3), 4.16 (2H, s, CH2C), 7.41 (2H, d, J = 8.1 Hz, 2,6-
CH of Ar), 7.68 (2H, d, J = 8.1 Hz, 3,5-CH of Ar), 7.97 (1H, s, H-5), 11.35 (1H, s, NH), 
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11.54 (1H, s, NH); δC (DMSO-d6): 22.6, 36.5, 99.5, 107.63, 125.4, 129.0, 129.5, 136.5, 144.3, 
150.4, 150.5, 162.4, 163.4. HRMS (FAB): M++1, found 336.0966. C16H12F3N3O2 requires 
336.0960. 
  
3.2.32 8-Benzyl-2,4-bis(benzylamino)-6-methylpyrido[2,3-d]pyrimidin-7(8H)-one 15a 
8-Benzyl-2-(benzylsulfanyl)-6-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 13a (0.050 
g, 0.134 mmol) and BOP (77 mg, 0.174 mmol, 1.3 eq.) were suspended in acetonitrile (10 
mL, anhydrous) at room temperature.  DBU (31 µl, 0.201 mmol, 1.5 eq) was added dropwise 
and the reaction solution became heterogeneous.  After stirring for 10 min at room 
temperature, benzylamine (22 µl, 0.201 mmol, 1.5 eq) was added and the solution was stirred 
for a further 48 h.  The excess solvent was removed under reduced pressure and the resulting 
residue was purified by flash column chromatography to yield the title compound 15a as a 
pale yellow (0.040 g, 0.0867 mmol, 65%), m.p. > 230 °C. νmax (KBr): 3348, 3288, 3041, 
2992, 1643, 1612, 1591, 1211, 1151, 989, 761 cm-1; δH (DMSO-d6): 2.03 (3H, d, J = 0.9 Hz, 
CH3), 4.64 (2H, d, J = 6.3 Hz, CH2NH), 4.79 (2H, d, J = 4.8 Hz, CH2NH), 5.51 (2H, br s, NH 
x 2), 7.16 – 7.36 (15H, m, C6H5 x 3), 7.85 (1H, s, H-5); δC (DMSO-d6): 16.2, 44.3, 44.6, 91.1, 
126.6, 126.8, 127.4, 127.6, 127.9, 128.2, 128.2, 128.9, 138.6, 139.5, 140.4, 155.3. HRMS 
(FAB): M++H, found 462.2290. C29H27N5O requires 462.2294.   
 
3.2.33 8-Benzyl-2-(benzylamino)-6-methyl-4-(1-pyrrolidinyl)pyrido[2,3-d]pyrimidin-
7(8H)-one 15b 
8-Benzyl-2-(benzylsulfanyl)-6-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione  13a (0.150 
g, 0.134 mmol) and BOP (77 mg, 0.174 mmol, 1.3 eq.) were suspended in acetonitrile (10 
mL, anhydrous) at room temperature.  DBU (31 µl, 0.201 mmol, 1.5 eq.) was added dropwise 
and the reaction solution became heterogeneous.  After stirring for 10 min at room 
temperature pyrrolidine (17 µl, 1.5 eq) was added and the solution was stirred for a further 48 
h at room temperature.  The excess solvent was removed under reduced pressure and the 
resulting residue was purified by flash column chromatography to yield the title compound 
15b as an orange solid (0.033 g, 0.0775 mmol, 58%), m.p. > 230 °C.  νmax (KBr): 3348, 3128, 
1682, 1557, 1458, 1435, 1388, 1329, 1213, 977 cm -1; δH (DMSO-d6):  δH (DMSO-d6): 2.01 – 
1.85 (4H, m, CH2CH2), 2.03 (3H, s, CH3), 3.73 (2H, t, J = 6.5, CH2N), 4.24 (2H, t, J = 6.5, 
CH2N), 4.80 (2H, d, J = 5.8, C6H5CH2NH), 5.53 (2H, s, C6H5CH2N8), 7.17 – 7.27 (10H, m, 
C6H5 x 2), 7.17 – 7.27 (1H, br, NH), 7.85 (1H, s, H-5); δC (DMSO-d6): 17.1, 25.5, 44.2, 44.9, 
50.6, 93.1, 118.7, 126.8, 126.9, 127.7, 128.2, 128.4, 128.5, 133.1, 138.9, 141.2, 157.0, 160.0, 
162.9.  HRMS (FAB): M++H, found 426.2296. C26H27N5O requires 426.2294.   
 
3.2.34 2-(Benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone 16a   
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To a solution of 5,6-diamino-2-(benzylsulfanyl)-4(3H)-pyrimidinone (500 mg, 2.11 mmol) in 
ethanol (20 mL) was added biacetyl (353 µl, 4.02 mmol, 2 eq) dropwise at room temperature. 
The reaction mixture was refluxed at 80 °C for 24 hours. The excess solvent was removed 
under reduced pressure and the resulting yellow solid was triturated with diethyl ether to yield 
the title compound 16a as a pale yellow solid (511 mg, 1.71 mmol, 85%) m.p. >230 oC. νmax 
(KBr): 2993, 2866, 1675, 1579, 1543, 1445, 1386, 1264, 1163, 959, 821, 717, 639, 516 cm-1; 
δH (DMSO-d6): 2.58 (3H, s, CH3), 2.61 (3H, s, CH3), 4.52 (2H, s, CH2S), 7.26 – 7.47 (5H, m, 
C6H5), 12.95 (1H, s, NH); δC (DMSO-d6): 21.8, 22.6, 33.8, 127.4, 128.5, 128.6, 129.1, 136.8, 
152.6, 152.6, 158.8, 159.2, 160.4. HRMS (FAB): M++H, found 299.0971. C15H14N4OS 
requires 299.0967. 
 
3.2.35 2-(Benzylsulfanyl)-6,7-diphenyl-4(3H)-pteridinone 16b 
To a solution of 5,6-diamino-2-(benzylsulfanyl)-4(3H)-pyrimidinone (1000 mg, 4.03 mmol) 
in ethanol (20 mL) was added benzil (1270 mg, 6.04 mmol, 1.5 eq) at room temperature. The 
reaction mixture was heated at 85 °C for 24 hours. The excess solvent was removed under 
reduced pressure and the resulting yellow solid was triturated with diethyl ether (10 mL) to 
yield the title compound 16b as a pale yellow solid (1.498 g, 3.25 mmol, 88%) m.p. >230 oC. 
νmax (KBr): 3165, 2988, 1664, 1573, 1559, 1423, 1378, 1167, 976, 723 cm-1; δH (DMSO-d6): 
4.59 (2H, s, CH2S), 7.26 – 7.51 (15H, m, C6H5 x 3), 13.17 (1H, s, NH); δC (DMSO-d6): 34.0, 
127.4, 128.1, 128.2, 128.6, 128.7, 129.1, 129.4, 129.6, 129.7, 129.8, 136.7, 137.8, 138.0, 
150.4, 152.4, 156.8, 160.4, 160.8. HRMS (FAB): M++H, found 423.1282. C25H18N4OS  
requires 423.1280.  
 
3.2.36 2-(Benzylamino)-6,7-dimethyl-4(3H)-pteridinone 17a 
2-(Benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone 16a (100 mg, 0.335 mmol) was dissolved 
in dry DMF (3.0 mL). To this solution was added m-CPBA (3.0 eq, 1.01 mmol, 174 mg) and 
was stirred under nitrogen for 3 hours at room temperature. The solvent was then removed 
under reduced pressure and the resulting solid was dissolved in benzylamine (2.0 mL, 18.31 
mmol) and heated in the microwave at 110 °C for 1 hour. The excess solvent was removed 
under reduced pressure and the resulting residue was purified by flash chromatography to 
yield the title compound 17a as a yellow solid (89 mg, 0.316 mmol, 94%) m.p. >230 °C. νmax 
(KBr): 3413, 2925, 1666, 1590, 1535, 1447, 1414, 1268, 1036, 727 cm-1; δH (DMSO-d6): 2.47 
(3H, s, CH3), 2.48 (3H, s, CH3), 4.59 (2H, d, J = 5.6 Hz, CH2NH), 7.23 – 7.40 (5H, m, C6H5), 
7.60 (1H, br s, CH2NH), 9.59 (1H, s, NH); δC (DMSO-d6): 21.3, 22.5, 43.6, 126.1, 126.8, 
127.1, 128.3, 139.3, 146.8, 153.1, 155.1, 158.0, 162.2. HRMS (FAB): M++H, found 
282.1353. C15H15N5O requires 282.1355.  
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Similarly prepared were: 
3.2.38 6,7-Dimethyl-2-(1-pyrrolidinyl)-4(3H)-pteridinone 17b: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone and pyrrolidine in 90% yield,  m.p. 
>230 °C. νmax (KBr): 3442, 3197, 2964, 1685, 1611, 1558, 1518, 392, 1270, 976 cm-1; δH 
(DMSO-d6): 1.91 (4H, t, J = 6.1 Hz, CH2CH2), 2.48 (3H, s, CH3), 2.49 (3H, s, CH3), 3.50 
(4H, t, J = 6.1, CH2N x 2), 11.34 (1H, s, NH); δC (DMSO-d6): 21.3, 22.5, 24.8, 46.9, 115.6, 
129.0, 147.0, 150.3, 154.7, 162.3. HRMS (FAB): found 246.1351. C12H15N5O requires 
246.1355.  
 
3.2.39 2-Anilino-6,7-dimethyl-4(3H)-pteridinone 17c: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone and aniline in 54% yield, m.p. >230 
°C ; νmax (KBr): 3318, 3013, 2922, 1663, 1590, 1454, 1405, 1323, 1232, 986, 741  cm-1; δH 
(DMSO-d6): 2.53 (3H, s, CH3), 2.55 (3H, s, CH3), 7.06 – 7.74 (5H, m, C6H5), 8.92 (1H, s, 
NHC6H5) 11.12 (1H, s, NH); δC (DMSO-d6): 21.4, 22.5, 99.5, 119.9, 123.1, 126.9, 128.8, 
138.3, 148.5, 149.1, 154.3, 158.7. HRMS (FAB): M++H, found 268.1201. C14H13N5O requires 
268.1198.  
 
3.2.40 2-(Allylamino)-6,7-dimethyl-4(3H)-pteridinone 17d: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone and allylamine in 86% yield,  m.p. 
>230 °C; νmax (KBr): 3278, 2934, 1688, 1621, 1546, 1498, 1312, 1225, 1064 cm-1; δH 
(DMSO-d6): 2.50 (6H, s, 2 x CH3), 3.90 (2H, s, CH2CH=), 5.02 (1H, dd, J = 10.3, 1.6 Hz), 
5.15 (1H, dd, J = 17.2, 1.6 Hz), 5.93 – 5.99 (1H, m, CH2CH=), 12.30 (1H, s, NH). HRMS 
(FAB): M++Na, found 254.1020. C11H13N5ONa requires 254.1018;  
 
3.2.41 2-(Benzylamino)-6,7-diphenyl-4(3H)-pteridinone 17e: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone and benzylamine in 83% yield, m.p. 
>230 °C; νmax (KBr): 3422, 3260, 3019, 1686, 1622, 1560, 1535, 1490, 1451, 1357, 1277, 
1036, 727 cm-1; δH (DMSO-d6): 4.66 (2H, d, J = 5.8 Hz, CH2), 7.23 – 7.42 (16H, m, C6H5 x 3 
and NH), 11.46 (1H, s, NH); δC (DMSO-d6): 43.8, 127.0, 127.2, 127.4, 128.0, 128.1, 128.4, 
129.0, 129.6, 138.2, 138.4, 138.8, 146.8, 152.8, 155.2, 156.5, 160.7. HRMS (FAB): M++H, 
found 406.1665. C25H19N5O requires 406.1668.  
 
3.2.42 6,7-Diphenyl-2-(1-pyrrolidinyl)-4(3H)-pteridinone 17f: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone and pyrrolidine in 83% yield m.p. 
>230 °C; νmax (KBr): 3421, 3201, 2971, 1681, 1610, 1556, 1516, 1453, 1287, 980, 765 cm-1; 
δH (DMSO-d6): 1.95 (4H, t, J = 6.5 Hz, CH2CH2), 3.57 (4H, t, J = 6.5 Hz, CH2N), 7.30 – 7.43 
(10H, m, C6H5), 11.13 (1H, s, NH); δC (DMSO-d6): 24.8, 47.1, 126.3, 127.9, 128.0, 129.0, 
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129.4, 129.6, 131.1, 138.4, 138.5, 146.1, 151.3, 154.7, 156.5, 162.0. HRMS (FAB): M++H, 
found 370.1672. C22H19N5O requires 370.1668.  
 
3.2.43 2-Anilino-6,7-diphenyl-4(3H)-pteridinone 17g: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone and aniline in 61% yield, m.p. >230 
°C; νmax (KBr): 3423, 3089, 2924, 1729, 1641, 1539, 1492, 1313, 1185, 836, 781 cm-1; δH 
(DMSO-d6): 7.10 – 7.81 (15H, m, C6H5 x 3), 9.29 (1H, br s, NHCH2), 11.29 (1H, s,); δC 
(DMSO-d6): 120.3, 123.4, 128.0, 128.1, 128.2, 128.3, 128.8, 129.1, 129.5, 129.6, 138.2, 
138.3, 147.8, 150.5, 154.5, 156.7. HRMS (FAB): M++H, found 392.1509. C24H17N5O 
requires 392.1511.  
 
3.2.44 2-(Allylamino)-6,7-diphenyl-4(3H)-pteridinone 17h: 
From 2-(benzylsulfanyl)-6,7-diphenyl-4(3H)-pteridinone and allylamine in 79% yield, m.p. 
>230 °C; νmax (KBr): 3288, 2931, 1685, 1623, 1563, 1496, 1287, 1095, 765 cm-1; δH (DMSO-
d6): 4.07 (2H, m, NHCH2-CH=), 5.15 (1H, dd, J = 10.3, 1.6 Hz, CH=CHH), 5.25 (1H, dd, J = 
17.2, 1.6 Hz, CH=CHH), 5.94 – 5.99 (1H, m, CH2-CH=), 6.94 (1H, s, NH), 7.30 – 7.43 (10H, 
m, C6H5 x 2), 11.41 (1H, s, NH); δC (DMSO-d6): 42.5, 115.6, 127.3, 128.0, 128.0, 129.1, 
129.4, 129.6, 134.8, 138.2, 146.7, 152.6, 155.2, 156.5, 160.6.  HRMS (FAB): M++H, found 
356.1510. C21H17N5O requires 356.1511. 
 
3.2.45 2-(Benzylsulfanyl)-N-butyl-6,7-dimethyl-4-pteridinamine 18a: 
2-(Benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone 16a (100 mg, 0.335 mmol) and BOP (196 
mg, 0.443 mmol, 1.3 eq) were suspended in dry acetonitrile (10 mL). DBU (76 µl, 0.493 
mmol, 1.5 eq) was then added dropwise and the reaction mixture became homogeneous. After 
stirring for 10 min at room temperature, butylamine (50 µl, 0.502 mmol, 1.5 eq) was added 
dropwise and the solution was stirred for a further 48 hours. The excess solvent was removed 
under reduced pressure and the resulting residue was partitioned between ethyl acetate and 
water. The organic layer was dried over MgSO4 and purified by flash chromatography  to 
yield the title compound 18a as pale yellow solid (92 mg, 78%),  m.p. >230 °C. νmax (KBr): 
3423, 3027, 2928, 1676, 1602, 1495, 1454, 1388, 750 cm-1; δH (CDCl3): 0.98 (3H, t, J = 7.2 
Hz, CH3), 1.40 – 1.50 (2H, m, CH2), 1.66 – 1.73 (2H, m, CH2), 2.64 (3H, s, CH3), 2.71 (3H, s, 
CH3), 3.63 (2H, t, J = 6.5 Hz), 4.57 (2H, s, CH2S), 6.93 (1H, m, NH) 7.22 – 7.48 (5H, m, 
C6H5); δC (CDCl3): 11.8, 20.1, 22.3, 23.3, 31.4, 35.9, 40.7, 122.2, 127.0, 128.4, 128.4, 128.5, 
129.2, 137.6, 150.1, 152.2, 159.1, 159.9, 171.6. HRMS (FAB): M++Na, found 376.1573. 
C19H23N5SNa requires 376.1572.  
 
Similarly prepared were 
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3.2.46 N-Benzyl-2-(benzylsulfanyl)-6,7-dimethyl-4-pteridinamine 18b: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone and benzylamine in 87% yield, m.p. 
>230 °C; νmax (KBr): 3403, 3084, 2981, 1684, 1621, 1574, 1448, 1223, 909  cm-1; δH (DMSO-
d6): 2.63 (6H, s, CH3 x 2), 4.39 (2H, s, CH2S), 4.71 (2H, d, J = 6.2, Hz, CH2NH), 7.19 – 7.44 
(10H, m, C6H5 x 2), 9.10 (1H, t, J = 6.2 Hz, CH2NH); δC (DMSO-d6): 22.0, 23.0, 34.4, 43.6, 
121.6, 126.9, 127.3, 128.3, 128.4, 128.6, 128.7, 138.3, 138.9, 150.8, 151.7, 159.0, 160.3, 
169.4. HRMS (FAB): M++H, found 388.1593. C22H21N5S requires 388.1596. 
 
3.2.47 2-(Benzylsulfanyl)-6,7-dimethyl-4-(1-pyrrolidinyl)pteridine 18c: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone and pyrrolidine in 81% yield, m.p. 
>230 °C; νmax (KBr): 3368, 3121, 2963, 1644, 1568, 1553, 1450, 1378, 1262, 820, 724  cm-1; 
δH (DMSO-d6): 2.02 – 1.86 (4H, m, CH2CH2), 2.56 (3H, s, CH3), 2.59 (3H, s, CH3), 3.67 (2H, 
t, J = 6.6, Hz, CH2N), 4.21 (2H, t, J = 6.6 Hz, CH2N), 4.44 (2H, s, CH2S), 7.21 – 7.45 (5H, m, 
C6H5); δC (DMSO-d6): 22.1, 22.7, 23.1, 26.4, 34.4, 49.8, 50.9, 123.5, 126.9, 128.4, 128.7, 
138.5, 148.8, 153.3, 156.7, 158.4, 168.3. HRMS (FAB): M++H, found 352.1599. C19H21N5S 
requires 352.1596.  
 
3.2.48 2-(Benzylsulfanyl)-6,7-dimethyl-N-phenyl-4-pteridinamine 18d: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone and aniline in 65% yield, m.p. >230 
°C; νmax (KBr): 3451, 3096, 1681, 1574, 1541, 1483, 1241, 1090, 828, 741 cm-1; δH (DMSO-
d6): 2.68 (3H, s, CH3), 2.70 (3H, s, CH3), 4.45 (2H, s, CH2S), 7.45 – 7.21 (10H, m, C6H5 x 2), 
10.09 (1H, s, NH); δC (DMSO-d6): 22.0, 23.0, 34.5, 121.6, 122.0, 124.2, 126.9, 128.4, 128.5, 
128.8, 138.0, 151.5, 152.0, 157.0, 160.8, 169.2.  HRMS (FAB): M++H, found 
374.1436.C21H19N5S requires 374.1439.  
 
3.2.49 2-(Benzylsulfanyl)-6,7-dimethyl-N-(4-methylphenyl)-4-pteridinamine 18e: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-pteridinone and p-toluidine in 71% yield, m.p. 
>230 °C; νmax (KBr): 3430, 3030, 2845, 1683, 1539, 1478, 1234, 1025, 697 cm-1; δH (DMSO-
d6): 2.29 (3H, s, C6H4CH3), 2.67 (3H, s, CH3), 2.70 (3H, s, CH3), 4.44 (2H, s, CH2S), 7.17 – 
7.77 (9H, m, C6H5 and C6H4), 10.03 (1H, s, NH); δC (DMSO-d6): 20.5, 22.0, 23.0, 34.4, 
121.6, 122.0, 127.0, 128.4, 128.8, 128.9, 133.3, 135.6, 138.0, 151.4, 152.0, 156.9, 160.6, 
169.2.  HRMS (FAB): M++H, found 388.1597. C22H21N5S requires 388.1596. 
  
3.2.50 2-(Benzylsulfanyl)-N-(4-ethylphenyl)-6,7-dimethyl-4-pteridinamine 18f: 
From 2-(benzylsulfanyl)-6,7-dimethyl-4(3H)-and 4-ethylaniline in 71% yield, m.p. >230 °C. 
νmax (KBr): 3424, 3026, 2942, 2853, 1678, 1513, 1495, 1392, 1259, 1012, 744 cm-1; δH 
(DMSO-d6): 1.18 (3H, t, J = 7.6 Hz, CH3), 2.59 (2H, q, J = 7.6 Hz, CH2), 2.67 (3H, s, CH3), 
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2.70 (3H, s, CH3), 4.44 (2H, s, CH2S), 7.20 – 7.80 (9H, m, C6H5 and C6H4), 10.03 (1H, s, 
NH); δC (DMSO-d6): 15.6, 22.0, 23.0, 27.6, 34.5, 121.6, 122.1, 126.9, 127.7, 128.4, 128.8, 
135.8, 138.0, 139.8, 151.4, 152.0, 156.9, 160.7, 169.2. HRMS (FAB): M++H, found 
402.1756. C23H23N5S requires 402.1752.  
 
3.2.51 N-Benzyl-6,7-dimethyl-4-(1-pyrrolidinyl)-2-pteridinamine 19a 
2-(Benzylsulfanyl)-6,7-dimethyl-4-(1-pyrrolidinyl)pteridine 18c (100 mg, 0.285 mmol) was 
dissolved in dry DMF (3.0 mL). To this was added m-CPBA (147 mg, 0.852 mmol, 3.0 eq) at 
room temperature and the reaction was stirred for 3 hours under nitrogen. The excess solvent 
was removed and the residue was dissolved in benzylamine (2.0 mL, 18.31 mmol) and the 
solution was heated in a microwave for 1 hour at 110 °C. The excess solvent was removed 
under reduced pressure and the resulting residue was purified by flash chromatography to 
yield the title compound 19a as a yellow solid (40 mg, 0.120 mmol, 42%), m.p. >230 °C. νmax 
(KBr): 3297, 2975, 1659, 1542, 1364, 1295, 981 cm-1; δH (DMSO-d6): 1.93 (4H, s, CH2CH2), 
2.47 (3H, s, CH3), 2.48 (3H, s, CH3), 3.95 (4H, br s, CH2N), 4.58 (2H, d, J = 4.8, CH2NH), 
6.84 (1H, br s, NH), 7.18 – 7.37 (5H, m, C6H5); δC (DMSO-d6): 21.8, 22.5, 45.0, 50.2, 122.9, 
126.8, 127.7, 128.5, 141.5, 144.0, 156.3, 157.3, 158.9, 161.1. HRMS (FAB): M++H, found 
335.1987. C19H22N6 requires 335.1984.  
 
Similarly prepared was 
3.2.52 6,7-Dimethyl-2,4-di(1-pyrrolidinyl)pteridine 19b 
From 2-(benzylsulfanyl)-6,7-dimethyl-4-(1-pyrrolidinyl)pteridine 18 c and pyrrolidine in 86% 
yield, m.p. >230 °C; νmax (KBr): 3098, 2975, 1683, 1620, 1467,1346, 1234, 1082, 830  cm-1; 
δH (DMSO-d6): 1.90 (8H, s, CH2CH2 x 2), 2.46 (3H, s, CH3), 2.48 (3H, s, CH3), 3.51 (4H, s, 
CH2N x 2), 3.68 (2H, s, CH2N), 4.18 (2H, s, CH2N); δC (DMSO-d6): 21.8, 22.8, 25.4, 46.8, 
50.1, 122.3, 143.6, 156.3, 157.2, 158.5, 159.1. HRMS (FAB):  M++H, found 299.1987. 
C16H22N6 requires 299.1984.  
 
Prepared by the same method as 15a and 15b were: 
3.2.53 N2-Allyl-N4-butyl-6,7-diphenyl-2,4-pteridinediamine 19c 
From 2-(allylamino)-6,7-diphenyl-4(3H)-pteridinone 17h and n-butylamine in 70% yield, 
m.p. >230 °C. νmax (KBr): 3283, 3080, 2974, 1691, 1616, 1560, 1492, 1220, 903, 735  cm-1; 
δH (DMSO-d6): 0.93 (3H, t, J = 7.3 Hz, CH3), 1.31 – 1.40 (2H, m, CH2), 1.60 – 1.67 (2H, m, 
CH2), 3.63 (2H, q, J = 6.5 Hz, CH2CH2NH), 4.02 (2H, t, J = 5.6 Hz, CH2CH=), 5.06 (2H, dd, 
J = 10.2, 1.6 Hz, CH=CHH), 5.18 (2H, dd, J = 17.2, 1.6 Hz, CH=CHH), 5.95 (1H, m, 
CH=CH2), 7.29 – 7.44 (11H, m, C6H5 and NH) 8.16 (1H, s, NH). HRMS (FAB): M++H, 
found 411.2298. C25H26N6 requires 411.2297.  
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3.2.54 N2-Allyl-N4-benzyl-6,7-diphenyl-2,4-pteridinediamine 19d 
From 2-(allylamino)-6,7-diphenyl-4(3H)-pteridinone 17h and benzylamine in 83% yield, m.p. 
>230 °C. νmax (KBr): 3310, 3054, 2986, 1663, 1621, 1446, 1421, 1263, 993, 895, 739 cm-1; δH 
(DMSO-d6): 4.01 (2H, s, C6H5CH2NH), 4.75 (2H, d, J = 5.2, Hz, CH2CH=) 5.05 (1H, dd, J = 
10.0, 1.6 Hz, CH=CHH), 5.18 (1H, dd, J = 17.2, 1.6 Hz, CH=CHH), 5.94 (1H, m, CH=CH2), 
7.21 – 7.45 (16H, m, C6H5 x 3 and NH), 8.67 (1H, s, NH); δC (DMSO-d6): 43.2, 43.3, 114.8, 
126.7, 127.4, 127.8, 128.0, 128.2, 128.8, 129.5, 129.6, 136.0, 138.4, 138.9, 139.4, 144.8, 
160.0, 161.4. HRMS (FAB): M++H found 445.2136. C28H25N6 requires 445.2141.  
 
3.2.55 N-Allyl-6,7-diphenyl-4-(1-pyrrolidinyl)-2-pteridinamine 19e 
From 2-(allylamino)-6,7-diphenyl-4(3H)-pteridinone 17h and pyrrolidine in 80% yield, m.p: 
>230 °C.   νmax (KBr): 3304, 3063, 2951, 1696, 1612, 1439, 1412, 1249, 998, 755 cm-1; δH 
(DMSO-d6): 1.87 – 2.02 (4H, m, CH2CH2), 3.74 (2H, t, J = 6.5 Hz, CH2N), 4.02 (2H, d, J = 
5.6 Hz, CH2CH=), 4.26 (2H, t, J = 6.5, Hz, CH2N), 5.06 (1H, dd, J = 10.3, 1.7 Hz, 
CH=CHH), 5.19 (1H, dd, J = 17.2, 1.7 Hz, CH=CHH), 5.91 – 6.00 (1H, m), 7.29 – 7.45 
(11H, m, C6H5 x 2 and NH). HRMS (FAB): M++H, found 409.2139. C25H24N6 requires 
409.2141.  
  
3.2.56 2-(Benzylsulfanyl)-6,7,7-trimethyl-3,7-dihydro-4H-pyrimido[4,5-b][1,4]oxazin-4-
one 20 
2-(Benzylthio)-6-hydroxy-5-nitrosopyrimidin-4(3H)-one (300 mg, 1.14 mmol) was dissolved 
in ethanol (20 mL) to which sodium dithionite (496 mg, 2.85 mmol, 2.5 eq) in water (20 mL) 
was added dropwise at room temperature and allowed to stir for 4 h. The flask was covered 
with aluminium foil to protect from light. A light yellow solid was precipitated, which was 
filtered and washed with water (2 x 10 mL) and ether (2 x 10 mL). The resulting solid was 
suspended in a 1:1 water/ethanol mixture (20 mL). 3-Chloro-3-methylbutan-2-one (206 mg, 
1.5 eq) in ethanol (10 mL) was then added to the suspension and this mixture was heated to 
reflux. After 15 min sodium acetate (112 mg, 1.2 eq) in water (5 mL) was added dropwise 
and heating under reflux was continued for a further 3 h. The resulting mixture was allowed 
to cool to room temperature and then stored at 0 °C for 12 h. The resulting precipitate was 
filtered, washed with water (2 x 10 mL) and dry ether (2 x 10 mL) to yield the title compound 
20 as a beige solid (126 mg, 0.399 mmol, 35%), m.p. 222 – 224 °C. νmax (KBr): 3424, 2981, 
1658, 1561, 1312, 1239, 1121, 965, 705; cm-1; δH (DMSO-d6): 1.44 (6H, s, 7-CH3 x 2), 2.07 
(3H, s, 6-CH3), 4.36 (2H, s, CH2S), 7.41 – 7.20 (5H, m, C6H5), 12.63 (2H, br s, NH). HRMS 
(FAB): M++H, found 316.1119. C16H17N3O2S requires 316.1120.  
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Similarly prepared was: 
3.2.57 Ethyl 2-(benzylsulfanyl)-4-oxo-3,7-dihydro-4H-pyrimido[4,5-b][1,4]oxazine-6-
carboxylate 21 
From 2-(Benzylthio)-6-hydroxy-5-nitrosopyrimidin-4(3H)-one reduced with sodium 
dithionite and ethyl bromopyruvate in 30% yield, m.p. 205 – 207 °C. νmax (KBr): 3413, 3046, 
2873, 1700, 1681, 1539, 1234, 1025, 721, 697 cm-1; δH (DMSO-d6): 1.28 (3H, t, J = 7.1 Hz, 
CH3), 4.25 (2H, q, J = 7.1 Hz, CH2), 4.40 (2H, s, CH2S), 5.10 (2H, s, CH2O), 7.42 – 7.25 (5H, 
m, C6H5), 13.00 (1H, br s, NH). HRMS (FAB): M++H, found 346.0863. C16H15N3O4S 
requires 346.0862.  
 
3.2.58 2-(Benzylamino)-6,7,7-trimethyl-3,7-dihydro-4H-pyrimido[4,5-b][1,4]oxazin-4-
one 22 
2-(Benzylsulfanyl)-6,7,7-trimethyl-3,7-dihydro-4H-pyrimido[4,5-b][1,4]oxazin-4-one 20 
(100 mg, 0.32 mmol) was dissolved in benzylamine (2.0 mL, 18.31 mmol) and the solution 
was heated in a microwave for 1 hour at 110 °C. The excess solvent was removed under 
reduced pressure and the residue was dissolved in ethyl acetate (10 mL) and washed with 
saturated sodium bicarbonate solution (2 x 5 mL) and water (2 x 5 mL).  The organic layer 
was then dried over MgSO4 and was purified by flash chromatography to yield the title 
product as a beige solid (44 mg, 0.148 mmol, 37%), m.p. >230 °C. νmax (KBr): 3425, 3283, 
2992, 1643, 1551, 1213, 1303, 1239, 1091, 705 cm-1; δH (DMSO-d6): 1.36 (6H, s, CH3 x 2), 
2.00 (3H, s, CH3), 4.43 (2H, d, J = 6.3 Hz, CH2NH), 7.15 (1H, br s, NH), 7.25 – 7.35 (5H, m, 
C6H5), 10.63 (1H, s, NH). HRMS (FAB): M++H, found 299.1506. C16H18N4O2 requires 
299.1508.  
 
3.2.59 N-Benzyl-2-(benzylamino)-4-oxo-3,7-dihydro-4H-pyrimido[4,5-b][1,4]oxazine-6-
carboxamide 23 
Ethyl 2-(benzylsulfanyl)-4-oxo-3,7-dihydro-4H-pyrimido[4,5-b][1,4]oxazine-6- 
carboxylate 21 (100 mg, 0.29 mmol) was dissolved in benzylamine (2.0 mL, 18.31 mmol) 
and the solution was heated in a microwave for 1 hour at 110 °C. The excess solvent was 
removed under reduced pressure and the residue was dissolved in ethyl acetate (10 mL) and 
washed with saturated sodium bicarbonate solution (2 x 5 mL) and water (2 x 5 mL).  The 
organic layer was then dried over MgSO4 and the title product was recrystallised from 
methanol as an orange solid (34 mg, 0.088 mmol, 30%), m.p. >230 °C. νmax (KBr): 3423, 
3005, 2873, 1701, 1669, 1539, 1234, 1025, 697 cm-1; δH (DMSO-d6): 4.36 (2H, d, J = 6.4 Hz, 
CH2NH), 4.36 (2H, d, J = 5.9 Hz, CH2NH), 5.00 (2H, s, CH2O) 7.29 (10H, m, C6H5 x 2), 7.52 
(1H, s, NH), 8.69 (1H, s, NH), 10.95 (1H, s, NH); δC (DMSO-d6): 42.1, 43.7, 63.1, 126.7, 
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127.1, 127.3, 127.4, 128.2, 128.4, 138.4, 139.4, 142.3, 153.8, 159.3, 162.0, 162.3. HRMS 
(FAB): M++H, found 390.1570. C21H19N5O3 requires 390.1566.  
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Abbreviations for reagents 
BOP (1-benzotriazolyl)oxy tris(dimethylamino) phosphonium 
hexafluorophosphate 
m-CPBA  m-chloroperbenzoic acid 
DBU  1,8-diazabicyclo[5,4,0]undec-7-ene 
TBD  1,5,7-triazabicyclo[4.4.0]dec-5-ene
 34
Legends for figures. 
 
Scheme 1. Substitution by Claisen rearrangement.Reagents and conditions:  i.  DMF, K2CO3, 
100 °C, 20 h;  ii.  200 °C, 24 h 
Scheme 2. Preparation of dialkylated pyrimidine 5 Reagents and conditions:  i.  DMF, 
K2CO3, 55 °C, 24h 
Scheme  3. Reagents and conditions:  i. DMF, r.t, 7 d; ii.  TBD or DBU, MW, 100 °C, 30 
min 
Scheme 4. Regents and conditions:  i.  Cs2CO3, KI, r.t., 24 h;  ii.  TiCl4.2THF, THF, 
reflux, 3 d 
 
Scheme 5. Proposed mechanism for the synthesis of derivatives 11 
 
Scheme 6. Diversification reactions for pyrrolopyrimdines. Reagents and conditions:  i. 
DMF, m-CPBA, r.t., 3 h;  ii, appropriate amine, MW, 110 °C, 1 h;  iii, BOP, CHCN, r.t., 
10 min;  iv,  DBU, appropriate amine, r.t., 48 h. 
 
Scheme 7. Diversification reactions for pteridines. Reagents and conditions: i, HNO2; ii, 
Na2S2O4; iii, EtOH, reflux; iv, DMF, m-CPBA, r.t., 3 h;  v, appropriate amine, MW, 110 °C, 1 
h;  vi, BOP, CH3CN, r.t., 10 min;  vii,  DBU, appropriate amine, r.t., 48 h. 
Scheme 8. Diversification for pyrimidooxazines. Reagents and conditions: i, HNO2; ii, 
Na2S2O4; iii, aq. EtOH, NaOAc, reflux; i iv PhCH2NH2, MW, 110 oC, 1 h. 
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